Insulin delivery company Insulet Corporation (NASDAQ: PODD) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 19.2% year on year to $842 million. Its non-GAAP profit of $1.99 per share was 25.4% above analysts’ consensus estimates.

Is now the time to buy PODD? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Insulet’s latest quarter saw revenue and profit above Wall Street’s expectations, with management crediting international expansion and operational improvements as primary drivers. CEO Ashley McEvoy pointed to nearly 20% year-over-year revenue growth, highlighting strong momentum in both U.S. and international markets, particularly from an expanding customer base and successful execution of type 2 diabetes initiatives. McEvoy emphasized the significance of new product launches and enhanced manufacturing productivity in supporting margin expansion and providing a solid foundation for recurring revenue. Management also highlighted continued investment in commercial capabilities and a broadened prescriber base, calling out early progress in their type 2 diabetes action plan as key to recent performance.

Looking ahead, management expects innovation and new product launches to be central to sustaining Insulet’s growth, even as competition intensifies. The upcoming launch of Omnipod 6 and continued development of a fully closed-loop system for type 2 diabetes are seen as significant milestones. CFO Flavia Pease noted, “We plan to take a more conservative approach to our 2027 outlook, factoring in new competitors and a tougher comparison internationally.” Management remains focused on driving market expansion, improving customer retention, and leveraging data-driven engagement tools, while cautioning that growth rates may moderate as the company builds on a larger revenue base and faces a dynamic competitive landscape.

Key insights from management’s remarks

Management attributed the quarter’s outperformance to robust international results, ongoing investments in commercial execution, and early benefits from new product launches, particularly in digital engagement and algorithm enhancements.

• International market momentum: Revenue growth outside the U.S. accelerated, driven by new country launches, upgrades from legacy products to Omnipod 5, and favorable price-mix realization. Management cited successful expansion into Spain and strong pediatric penetration in the U.K.
• Type 2 diabetes initiatives: Actions to improve type 2 customer retention included enhanced sales force training, compensation tied to retention, and expanded clinical support teams. Early signs show modest improvement in retention, with management expecting benefits to build over time.
• Omnipod Discover rollout: The full-market launch of Omnipod Discover, a digital engagement platform providing personalized insights, led to increased user confidence and stronger retention. Over 35,000 users and 5,000 clinicians have adopted the platform, supporting its potential as a differentiator.
• Algorithm and product enhancements: The upgraded Omnipod 5 algorithm, now in full retail, enables users to spend more time in automated mode, contributing to improved clinical outcomes. Integration with FreeStyle Libre 3 Plus sensors has expanded to additional markets, broadening the product’s appeal.
• Share repurchase authorization: Insulet’s Board approved an additional $1 billion in share repurchases, reflecting sufficient cash flow and balance sheet strength to return capital while maintaining growth investments.

Drivers of future performance

Management expects growth to be fueled by ongoing product innovation, a growing customer base, and improved retention, but signals that moderating growth rates are likely as the business scales and competition rises.

• Upcoming Omnipod 6 launch: The anticipated 2027 launch of Omnipod 6—a next-generation automated insulin delivery system—aims to address lifestyle needs and deliver stronger clinical outcomes with less manual intervention. Management believes coordinated global launches and enhanced field preparation will maximize uptake.
• Fully closed-loop system for type 2 diabetes: Insulet is advancing a user-friendly, fully closed-loop device for type 2 patients, designed to require minimal user input. Clinical studies show improved time-in-range metrics, and the company targets a pivotal trial submission in 2027 with a commercial launch planned for 2028.
• Competitive and market dynamics: Management acknowledges new entrants will likely result in some share loss in new customer starts, particularly in the U.S., and expects international growth to moderate as large launches and price-mix benefits from 2026 are not repeated. Nonetheless, the company expects to remain the market leader due to its large installed base and differentiated product offering.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will focus on (1) the pace and impact of the Omnipod Discover platform’s adoption on user retention and engagement, (2) progress in type 2 diabetes customer retention through revised sampling and onboarding programs, and (3) updates on the regulatory and commercial timelines for Omnipod 6 and the fully closed-loop type 2 system. Additional watch points include the effect of new competitive product launches on share dynamics and the outcome of ongoing PBM contract negotiations for U.S. access.

Insulet currently trades at $166, up from $154.86 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Stocks that trumped tariffs

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.